Human Milk-Based Fortification No Aid for Extremely Preterm Infants
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, Jan. 10, 2024 -- Human milk-based fortification does not aid outcomes in extremely preterm infants fed exclusively with breast milk, according to a study published online Jan. 2 in eClinicalMedicine.
Georg Bach Jensen, from Linköping University and Crown Princess Victoria Children's Hospital in Sweden, and colleagues randomly assigned (1:1) 228 extremely preterm infants (born between gestational week 22 + 0 and 27 + 6) who were fed exclusively human breast milk (mother's own and/or donor milk) to receive targeted fortification with either human milk-based fortifier (HMBF) or bovine milk-based fortifier (BMBF).
The researchers found that 35.7 percent of infants assigned to HMBF fulfilled the criteria of either necrotizing enterocolitis, sepsis, or death versus 34.5 percent of infants assigned to BMBF (odds ratio, 1.05; 95 percent confidence interval, 0.61 to 1.81; P = 0.86). There were no significant differences between the groups for adverse events.
"We acknowledge that the results of the present trial may need to be verified by other studies," the authors write. "Further, potential effects on growth and neurodevelopmental outcomes still remain to be evaluated, and such follow-up analyses from this study are ongoing."
One author disclosed ties to Prolacta Bioscience, which partially funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-01-11 00:15
Read more
- Racial, Ethnic Differences Seen in Cleft Lip Surgery Repair
- Election Fears Are Compromising the Sleep Health of Americans
- Just 5 Extra Minutes of Exercise Per Day Could Lower Blood Pressure
- ACG: Fewer Overt Hepatic Encephalopathy Episodes Seen With Rifaximin
- Prepping for Colonoscopy? An Expert Offers Tips to Make Things Easier
- In Utero Exposure to COVID-19 Not Tied to Later Neurodevelopmental Issues
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions